What's encouraging, however, is that there may be more benefits with GLP-1 drugs than simply losing weight and controlling ...
Eli Lilly’s Mounjaro is the only dual drug on the market, targeting GLP-1 and GIP. Doctors say that Mounjaro is also more ...
Jan 8 () - Eli Lilly said on Thursday a late-stage trial showed its weight-loss drug Zepbound, used with its psoriatic ...
In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...
Retatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage clinical trial, the company announced.
Arrowhead Pharma (ARWR) stock jumps as obesity drug ARO-INHBE doubles weight loss with Eli Lilly’s (LLY) GLP-1 therapy, ...
Eli Lilly and Company (NYSE:LLY) is one of the best long term growth stocks to buy according to hedge funds. On January 9, ...
Eli Lilly has further expanded its weight-loss initiatives with novel therapies such as orforglipron, an oral GLP-1 receptor ...
It sounds like Lilly did just that. The U.S. pharma announced Wednesday that it was paying $14 per share of Ventyx—more than ...
Eli Lilly will buy autoimmune drug developer Ventyx Biosciences for $1.2 billion in cash, the companies said on Wednesday, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback